Skip to content

tDCS to Enhance Cognitive Training in Schizophrenia

Does Transcranial Direct Current Stimulation (tDCS) Enhance Outcomes From Computerised Cognitive Remediation in Patients With Schizophrenia?

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01733602
Enrollment
52
Registered
2012-11-27
Start date
2012-11-30
Completion date
Unknown
Last updated
2017-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

The primary aim for the study is to determine whether transcranial direct current stimulation (tDCS) enhances training gains on cognitive training (CT) tasks. Secondary aims are to determine whether tDCS combined with CT causes larger transferable improvements on non-trained tasks (i.e., generalisation effects) and whether these generalisation effects are maintained over time (i.e., maintenance effects). Specific hypotheses are: 1. CT combined with active tDCS will produce greater training gains on CT tasks compared to a similar control group receiving CT with sham tDCS. 2. CT combined with active tDCS will produce greater generalisation effects on non-trained cognitive tasks compared to CT with sham tDCS. 3. The cognitive improvements gained by patients from both interventions will be maintained over 1 month follow-up.

Interventions

DEVICEtranscranial direct current stimulation

Sponsors

The University of New South Wales
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Subjects are 18 years of age or above. 2. Subjects meet criteria for a DSM -IV schizophrenia or schizoaffective disorder but with a stable mental status as demonstrated by a stable Positive and Negative Symptom Score (PANSS) score over a period of 2 weeks. 3. Subjects have had no medication changes in the 2 weeks prior to obtaining informed consent. 4. Subjects are right-handed. 5. Subjects able to give informed consent for the trial.

Exclusion criteria

1. Drug or alcohol abuse or dependence (preceding 3 months). 2. Concurrent anticonvulsant or long acting benzodiazepine medication, as these medications may interfere with the effects of tDCS. 3. Subject requires a rapid clinical response due to inanition, psychosis or high suicide risk. 4. Clinically defined neurological disorder or insult, including history of seizures, cerebral aneurysm or trauma, significant head trauma with loss of consciousness for ≥ 30 minutes. 5. Subject has metal in the cranium, skull defects, or skin lesions on scalp at proposed electrode sites. 6. Female subject of child bearing age, sexually active and not using reliable contraception

Design outcomes

Primary

MeasureTime frame
Progression score on cognitive training task.Post treatment

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026